This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



azilsartan medoxomil (Edarbi®)


Reference No. 753

Publication date:
01/05/2012


Appraisal information

azilsartan medoxomil (Edarbi®) 20 mg tablet
azilsartan medoxomil (Edarbi®) 40 mg tablet
azilsartan medoxomil (Edarbi®) 80 mg tablet


Company: Takeda UK Ltd
BNF category: Cardiovascular system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 25/04/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, azilsartan medoxomil (Edarbi®) cannot be endorsed for use within NHS Wales for the treatment of essential hypertension in adults.
Statement of Advice (SOA)
Download